Research
Two Paths Towards Alzheimer's – Now They Are Becoming One
Article no. 39 · August 1, 2026 · Updated September 20, 2026 ·
Alzheimer's research has long followed two different paths. One has sought the medicine. The other has tried to strengthen the individual. Now, these two paths are starting to converge.
These two tracks are driven by different forces. On the pharmaceutical side, universities and hospitals work together with pharmaceutical companies. On the lifestyle side, universities instead work closely with non-profit Alzheimer's organizations.
The Hunt for the Molecule
Universities, university hospitals, and pharmaceutical companies are trying to understand the biological mechanisms driving the disease and develop drugs that can influence them.
First, amyloid was central. Then followed tau, inflammation, metabolism, blood vessels, and the energy supply of nerve cells.
The work has been enormous. Hundreds of drugs have been tested. Some have been approved. These are important advances. But they do not cure the disease, and they only slow its progression to a limited extent.
The hunt continues.
The Path That Began in Finland
At the same time, another research track emerged, starting in Finland in 2009 (Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability FINGER).
Not in the pharmaceutical industry but at universities. And often with funding from non-profit organizations.
The Finnish study was based on a simple but radical idea. Perhaps Alzheimer's is not a disease that should be met with a single treatment.
Several risk factors should be addressed simultaneously:
- Exercise
